Description
Vesicular monoamine transporter 2 (VMAT2) is a member of the SLC18 family of transporters that is encoded by SLC18A2 in humans.{55233} VMAT2 is expressed in monoaminergic neurons of the central and peripheral nervous systems and localizes to synaptic vesicles where it transports cytosolic dopamine (DA), serotonin (5-HT), norepinephrine (NE), and histamine into synaptic vesicles, regulating cytoplasmic levels and exocytosis of monoamine neurotransmitters. It consists of 12 transmembrane helices, which contain a luminal loop subject to N-glycosylation, as well as cytoplasmic N- and C-terminal domains that regulate monoamine transport and VMAT2 localization, respectively.{54273} Homozygous knockout of Slc18a2 completely eliminates brain DA, 5-HT, and NE and induces postnatal lethality in mice.{54274} Slc18a2+/- mice exhibit increased apomorphine-, cocaine-, amphetamine-, or ethanol-induced horizontal locomotor activity compared to wild-type mice. Slc18a2 overexpression decreases immobility time in the forced swim test and marble burying in mice.{54275} Slc18a2 overexpression also reduces the loss of dopaminergic neurons in a mouse model of Parkinson’s disease induced by MPTP. SNPs in SLC18A2 have been found in individuals with bipolar disorder, schizophrenia, drug addiction, and Parkinson’s disease.{55233} Cayman’s VMAT2 (C-Term) Polyclonal Antibody can be used for Western blot (WB) applications. The antibody recognizes VMAT2 at approximately 57 kDa from human and rat samples.
Synonyms:
Immunogen: Peptide from the intracellular C-terminal region of human VMAT2 conjugated to KLH
Formulation: 100 µl of affinity-purified pooled sheep polyclonal antibody
Isotype:
Applications: WB
Origin:
Stability: 365 days
Application|Western Blot||Product Type|Antibodies|Polyclonal Antibodies||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research||Research Area|Neuroscience|Behavioral Neuroscience|Anxiety||Research Area|Neuroscience|Behavioral Neuroscience|Bipolar Disorder||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Behavioral Neuroscience|Schizophrenia & Psychosis||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease
